Neumora Therapeutics (NMRA) EPS (Weighted Average and Diluted) (2022 - 2026)
Neumora Therapeutics (NMRA) recorded quarterly EPS (Weighted Average and Diluted) of -$0.3 in Q1 2026, up 14.29% quarter-over-quarter from -$0.35 in Q4 2025, and up 28.57% on a YoY basis from -$0.23 in Q1 2025.
Neumora Therapeutics (NMRA) EPS (Weighted Average and Diluted) (2022 - 2026) Analysis & Trends
Neumora Therapeutics' EPS (Weighted Average and Diluted) history runs 5 years deep, the most recent figure standing at -$0.3 for Q1 2026.
- In Q1 2026, EPS (Weighted Average and Diluted) rose 28.57% year-over-year to -$0.3; the TTM figure through Mar 2026 stood at -$1.33 (up 17.39% YoY), while the FY2025 annual figure was -$1.45, up 5.23% from the prior year.
- EPS (Weighted Average and Diluted) was -$0.3 for Q1 2026 at Neumora Therapeutics, up from -$0.35 in the prior quarter.
- In the past five years, EPS (Weighted Average and Diluted) ranged from a high of -$0.04 in Q4 2023 to a low of -$1.28 in Q2 2023.
- Historically, EPS (Weighted Average and Diluted) has averaged -$0.6 across 5 years, with a median of -$0.37 in 2024.
- The sharpest annual moves came in 2023 and 2024: EPS (Weighted Average and Diluted) soared 95.92% in 2023, then slumped 825.0% in 2024.
- A 5-year view of EPS (Weighted Average and Diluted) shows it stood at -$0.98 in 2022, then jumped by 95.92% to -$0.04 in 2023, then plunged by 825.0% to -$0.37 in 2024, then rose by 5.41% to -$0.35 in 2025, then grew by 14.29% to -$0.3 in 2026.
- The last three EPS (Weighted Average and Diluted) figures came in at -$0.3 (Q1 2026), -$0.35 (Q4 2025), and -$0.35 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | 0.68 |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | 3.06 |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | 3,086.42 |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | 0.00 |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | - |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | 0.00 |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | 4.02 |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | -0.61 |
| 10 | Neumora Therapeutics | 320.17 Mn | 320.17 Mn | - | -0.30 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -0.30 |
| Dec 31, 2025 | -0.35 |
| Sep 30, 2025 | -0.35 |
| Jun 30, 2025 | -0.33 |
| Mar 31, 2025 | -0.42 |
| Dec 31, 2024 | -0.37 |
| Sep 30, 2024 | -0.45 |
| Jun 30, 2024 | -0.37 |
| Mar 31, 2024 | -0.34 |
| Dec 31, 2023 | -0.04 |
| Sep 30, 2023 | -1.14 |
| Jun 30, 2023 | -1.28 |
| Mar 31, 2023 | -1.22 |
| Dec 31, 2022 | -0.98 |
| Sep 30, 2022 | -1.06 |